TROP-2–Directed ADC Could Be New Standard for Some NSCLCs

In the phase III Opti-TROP-Lung06 trial, patients with newly diagnosed PD-L1-negative, advanced nonsquamous non-small cell lung cancer without targetable alterations who received the TROP-2-directed antibody-drug conjugate sacituzumab tirumotecan and the PD-1 inhibitor pembrolizumab experienced a median progression-free survival (PFS) of 15 months. In comparison, those patients who received standard chemotherapy plus pembrolizumab experienced a median PFS of 5.7 months.

Publication Details

Journal
Cancer Discovery
Published
2026-11-14
DOI
https://doi.org/10.1158/2159-8290.cd-nw2026-0107
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

TROP-2–Directed ADC Could Be New Standard for Some NSCLCs

Cancer Discovery
Lung Cancer Treatments and Mutations
article

TROP-2–Directed ADC Could Be New Standard for Some NSCLCs

article en

Abstract

In the phase III Opti-TROP-Lung06 trial, patients with newly diagnosed PD-L1-negative, advanced nonsquamous non-small cell lung cancer without targetable alterations who received the TROP-2-directed antibody-drug conjugate sacituzumab tirumotecan and the PD-1 inhibitor pembrolizumab experienced a median progression-free survival (PFS) of 15 months. In comparison, those patients who received standard chemotherapy plus pembrolizumab experienced a median PFS of 5.7 months.

Cancer Discovery
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon